Showing 396 results
- Media Release /New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates and MRI lesion activity and prolonged time to…
- Media Release /
- Media Release /Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of…
- Media Release /EAST HANOVER, N.J., Dec. 11, 2019 /PRNewswire/ -- The submission is based on positive results from the Phase III POLYP 1 and POLYP 2 studies of Xolair in adults with chronic rhinosinusitis with…
- Media Release /Black women with breast cancer are approximately 40% more likely to die compared to white women with breast cancer in the U.S.[1] - and are also more likely to be diagnosed at a later stage with…
- Media Release /
- Media Release /
- Story /
More than 16 teams from US universities participated in the first US oncology data science hackathon to tackle current challenges in metastatic breast cancer treatments.
- Media Release /- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
- Media Release /- 94% of patients regained their PASI 75 response and the majority re-achieved their PASI 90 or 100 response after 16 weeks of Cosentyx 300 mg retreatment(1)- Patients may need to pause treatment due…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 40
- › Next page